Docetaxel Combined With Cisplatin for Metastatic Extramammary Paget Disease

Clin Genitourin Cancer. 2018 Aug;16(4):e899-e901. doi: 10.1016/j.clgc.2018.03.004. Epub 2018 Mar 23.

Abstract

Introduction: Metastatic extramammary Paget disease (EMPD) as a rare intraepithelial carcinoma is fatal. However, no standardized chemotherapy has been established. We provided docetaxel combined with cisplatin to EMPD patients.

Patients and methods: A total of 8 patients with metastatic EMPD were included in this study between July 2010 and July 2015 (mean age, 64.4 years); they underwent a mean of 9.4 cycles of chemotherapy. All the patients were treated with chemotherapy (docetaxel 60 mg/m2 on day 1; cisplatin 25 mg/m2 on days 1-3) as first-line treatment for > 6 cycle (at least 21 days per cycle). Data on tumor response, time to progression, overall survival, and adverse events were collected.

Results: After 2 cycles of chemotherapy, 4 patients experienced partial remission and 4 stable disease. The mean overall survival was 28.9 months, and the mean progression-free survival was 9.9 months.

Conclusion: Docetaxel combined with cisplatin might be a treatment option for metastatic EMPD, with high disease control rate and good overall survival.

Keywords: Chemotherapy; Cisplatin; Docetaxel; Extramammary Paget's disease; Metastatic.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cisplatin / administration & dosage*
  • Cisplatin / therapeutic use
  • Docetaxel / administration & dosage*
  • Docetaxel / therapeutic use
  • Drug Administration Schedule
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Paget Disease, Extramammary / drug therapy*
  • Survival Analysis
  • Treatment Outcome

Substances

  • Docetaxel
  • Cisplatin